Clinical trials: Watch & Wait
Malignant Colorectal Polyp, Colorectal Cancer
Malignant Polyp Registry
The purpose of this study is to learn more about malignant colorectal polyps (early colorectal cancers removed during colonoscopy) and the risk that cancer remains, comes back, or spreads after the polyp is removed.
- Conditions
- Malignant Colorectal Polyp, Colorectal Cancer, T1 Colorectal Cancer
- Trial name
- NCT07619079
- Testing
- Questionnaires
- Where
- 7 sites in United States
- Volunteers
- 500 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Neoplasms
SCRT in TNT With or Without Chlorophyllin
The goal of this clinical trial is to see, if addition of chlorophyllin to neoadjuvant Chemo-radiotherapy can reduce the gastro-intestinal/genitourinary/hematological toxicity rates and improve the quality of life in patient's…
- Trial name
- SCOTCH (NCT05856305)
- Testing
- Chlorophyllin, Sodium Copper Complex
- Where
- 2 sites in India
- Volunteers
- 76 people
- Sponsor
- Tata Memorial Centre
Locally Advanced Rectal Cancer, Rectal Adenocarcinoma
Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer
This prospective national multicentre feasibility study evaluates dose-escalated short-course proton radiotherapy followed by total neoadjuvant chemotherapy in patients with primary high-risk locally advanced rectal…
- Trial name
- PROSPECT-WW (NCT07903883)
- Testing
- Intensity modulated proton therapy
- Where
- 8 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Patients With Locally Advanced Rectal Cancer
GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.
The evaluation of the tumor response to chemoradiotherapy/total neoadjuvant therapy (CRT/TNT) remains a challenge. The integration of a blood-based biomarker such as ctDNA with clinico-radiological tools could offer the potential…
- Trial name
- REVEAL (NCT05674422)
- Testing
- total neoadjuvant therapy
- Where
- 15 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
RECTAL NEOPLASMS, Rectal Cancer
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
This is an open-label, multi-center, single-arm clinical study. All patients received concurrent chemoradiation therapy (CRT) followed by 4 cycles of tislelizumab combined with CAPOX, then underwent clinical response assessment.
- Trial name
- NCT06390982
- Testing
- Radiotherapy, Tislelizumab, Capecitabine
- Volunteers
- 46 people
- Sponsor
- Fudan University
Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
The goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with…
- Trial name
- NCT07277842
- Testing
- Serplulimab, FOLFOXIRI chemotherapy, CAPOX chemotherapy
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
The purpose of this study is to compare chemotherapy plus immunotherapy with immunochemotherapy combined subsequent locoregional radiotherapy in recurrent nasopharyngeal carcinoma (NPC), in order to confirm the value of…
- Trial name
- NCT07088484
- Testing
- ICI-chemotherapy and LIMT
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Rectal Carcinoma
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
The aim of this clinical trial is to compare triplet induction therapy (FOLFOXIRI) with doublet induction therapy (CAPOX/FOLFOX), followed by chemoradiotherapy and either surgery or a watch-and-wait approach, in patients with…
- Trial name
- MEND-IT II (NCT07472868)
- Testing
- FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 20 sites in Netherlands
- Volunteers
- 394 people
- Sponsor
- J. W. A. Burger
Rectum Cancer
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
A phase II clinical trial compared standard TNT (mFolfox6 and CRT) with preoperative chemoradiotherapy (CRT) with neoadjuvant chemotherapy (CT) containing mFolfirinox in patients with locally advanced rectal cancer.
- Trial name
- NCT06812728
- Testing
- mFOLFIRINOX, mFolfox6
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Menoufia University
Clear-cell Metastatic Renal Cell Carcinoma
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy.
- Trial name
- A-PREDICT (NCT01693822)
- Testing
- Axitinib
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Gastrointestinal Cancer, Gastric Cancer
NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers
The NOMAD-GI study is a single-center, bidirectional cohort study designed to evaluate the safety and efficacy of molecular biomarker-guided non-operative management (NOM) and organ preservation strategies after precision therapy…
- Conditions
- Gastrointestinal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer
- Trial name
- NOMAD-GI (NCT07775859)
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
LOCALLY ADVANCED RECTAL CANCER
Organ Preservation in Locally Advanced Rectal Cancer
PRONAR trial aims to assess if treatment with organ preservation in stage II and III rectal cancer after a complete or almost complete response to neoadjuvant treatment is feasible and safe in our environment.
- Trial name
- PRONAR (NCT03064646)
- Testing
- Organ Preservation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Head and Neck Cancer
PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer
RATIONALE: Imaging procedures, such as PET/CT scan, produce pictures of areas inside the body and may help doctors detect residual disease and plan the best treatment.
- Trial name
- NCT00720070
- Testing
- positron emission tomography/computed tomography, therapeutic conventional surgery
- Where
- United Kingdom
- Volunteers
- 560 people
- Sponsor
- Warwick Medical School